UNSPSC 51361807: Taniplon

This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OKS0I0BBLP. European Medicines Agency schedules Taniplon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10830MIG. Taniplon generally arises in the molecular formula C14H15N5O2.

The term TANIPLON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, no. 3 1990, list 30.) TANIPLON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule taniplon under HS 29349990 and SITC 51579. As of Q4 2014, TANIPLON remains the US FDA Preferred Term for this commodity. Taniplon bears US NLM identifiers UMLS ID C2699891 and NCI Concept Code C76947. SMILES: O(C1NC2N(C3CCCCC13)CC(N2)C1NC(ON1)C)C.

UNSPSC 51361807 Taniplon is a Commodity code under which state and local governments procure naloxone, drug deactivation systems, generic pharmaceuticals, and over-the-counter products for community health, public safety, and pharmacy benefit programs. The code captures both emergency medical supplies and broader pharmaceutical sourcing for public agencies and cooperative purchasing alliances, reflecting a mix of immediate-response health interventions and systematic supply-chain management for recurring pharmaceutical needs.

State agencies, counties, and multistate cooperative purchasing alliances issue solicitations under this code. Seminole County, Florida (county health operations), the Texas Health and Human Services Commission (state pharmacy benefit program), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP, a multistate purchasing vehicle spanning state and local participants across multiple states including Oregon) represent the recent buyer mix. Recent opportunities include Seminole County's competitive IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB60459723LAS, due July 26, 2023), the Texas HHS Commission's RFI on Therapeutic Pharmacy Initiative direct-to-manufacturer prescription programs (HHS0017013, posted April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers including AmerisourceBergen and Cardinal Health (S1070000015802, due March 26, 2026). Activity concentrates in Florida, Texas, and the Upper Midwest (Minnesota and partnering states), with suppliers expected to meet cGMP and Drug Supply Chain Security Act compliance, maintain substantial insurance coverage, and accept pricing models ranging from fixed-fee to WAC-minus structures. Cooperative purchasing vehicles dominate the larger pharmaceutical procurements, while counties pursue direct buys for tactical health and safety supplies with quarterly or annual delivery cycles and fixed-price bidding.